Biotech News

Zai Lab Announces Participation in November Investor Conferences

Zai Lab Limited (ZLAB)Zai Lab LimitedCommercial

SHANGHAI, China and CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in November 2023:

Jefferies London Healthcare Conference Fireside Chat: Wednesday, November 15 th at 1:00 p.m. GMT Location: London

6th Annual Evercore ISI HealthCONx Conference Fireside Chat: Wednesday, November 29 th at 1:45 p.m. EST Location: Miami

A live webcast of the presentations will be available on the Investor Relations page of Zai Lab’s website at ir.zailaboratory.com/webcasts-presentations and archived replays will be available for up to 90 days following the completion of each event.

About Zai Lab

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, autoimmune disorders, infectious disease, and neuroscience. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.

For additional information about Zai Lab, including our products, business activities and partnerships, research, and other events or developments, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

For more information, please contact:

Investor Relations: Christine Chiou / Lina Zhang +1 (917) 886-6929 / +86 136 8257 6943 [email protected] / [email protected]

Media: Shaun Maccoun / Xiaoyu Chen +1 (415) 317-7255 / +86 185 0015 5011 [email protected] / [email protected]

Source: Zai Lab Limited

Related news

Zai Lab Limited

Zai Lab is a global biopharmaceutical company focused on oncology, infectious disease, and autoimmune disease. Its story combines commercial execution in Asia with a broad development pipeline and international reach.

Recent company news

Stock data

Close
20.88 USD
Market cap
1.93B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States